BidaskClub Lowers Endo International (NASDAQ:ENDP) to Strong Sell

BidaskClub downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a sell rating to a strong sell rating in a research report report published on Thursday morning, BidAskClub reports.

Several other equities research analysts also recently weighed in on the company. Morgan Stanley set a $70.00 target price on Edison International and gave the stock a hold rating in a research report on Monday, July 15th. Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. Gabelli reissued a hold rating on shares of Endo International in a report on Wednesday, March 27th. ValuEngine downgraded Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, May 28th. Finally, Citigroup reduced their price target on Thor Industries from $78.00 to $70.00 in a report on Monday, June 17th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the stock. Endo International presently has a consensus rating of Hold and a consensus price target of $10.73.

Shares of NASDAQ ENDP opened at $3.27 on Thursday. Endo International has a 1-year low of $3.21 and a 1-year high of $18.50. The stock has a 50-day moving average of $4.28. The stock has a market capitalization of $739.62 million, a P/E ratio of 1.19 and a beta of 1.15.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.42 by $0.11. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The company had revenue of $720.00 million during the quarter, compared to the consensus estimate of $692.31 million. During the same quarter in the prior year, the business earned $0.67 earnings per share. The company’s revenue was up 2.9% compared to the same quarter last year. On average, equities research analysts anticipate that Endo International will post 2.17 earnings per share for the current year.

In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now owns 148,309 shares of the company’s stock, valued at approximately $582,854.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.80% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Signition LP bought a new position in Endo International during the 1st quarter worth approximately $139,000. Factorial Partners LLC bought a new position in Endo International during the 1st quarter worth approximately $193,000. First Quadrant L P CA lifted its holdings in Endo International by 94.7% during the 1st quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after buying an additional 11,926 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Endo International by 61.4% during the 1st quarter. Nisa Investment Advisors LLC now owns 42,256 shares of the company’s stock worth $339,000 after buying an additional 16,077 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. lifted its holdings in Endo International by 5.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock worth $407,000 after buying an additional 2,795 shares during the last quarter. 93.59% of the stock is currently owned by institutional investors.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

See Also: How does a margin account work?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.